Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900
Central Ohio
Change Location

Ohio Emerges as a Major Model of Collaboration in Alzheimer’s Research as the State’s Alzheimer’s Population Is Projected to Grow

Ohio Emerges as a Major Model of Collaboration in Alzheimer’s Research as the State’s Alzheimer’s Population Is Projected to Grow
Share or Print this page
Share or Print this page
June 30, 2020
Share or Print this page
Dr. Alan Lerner looks at how Ohio is growing its Alzheimer’s research capabilities and reflects on the strong foundation set.

“Our roots go deep,” he said. “Many of the leaders of the field worked in Ohio, grew up in Ohio.” Today, “I’d say (Ohio) is square in the middle of the pack. The Cleveland Alzheimer’s Disease Research Center (CADRC) is a huge national acknowledgment of the progress,” said Lerner, who is co-director of the Clinical Core at the Alzheimer’s Disease Research Center and Director of the Brain Health and Memory Center at the Neurological Institute of University Hospitals Cleveland Medical Center. “It’s like ‘we know you are doing great things. Now you have a seat at the table.’”

Ohio is emerging as a major model of collaboration in the area of Alzheimer’s research as the state’s population living with Alzheimer’s grows. Today, 220,000 Ohioans age 65 and older live with Alzheimer’s disease. By 2025, that number is expected to climb to 250,000.

Eric VanVlymen, Executive Director of the Alzheimer’s Association in Ohio, said, Ohio has fantastic Alzheimer’s research areas and with the availability of research dollars, Ohio has the opportunity to use that funding to be a leader not only for Ohio residents but around the country. “When research comes to Ohio, that means they are also bringing the latest and greatest techniques to Ohio. If you live here, you have access to those things,” he said.

The Cleveland Alzheimer’s Disease Research Center, which was announced in July 2019, is a prime example of bringing together the expertise of some of Ohio’s top Alzheimer’s researchers and clinicians. Funded by the National Institute on Aging, part of the U.S. National Institutes of Health, the Cleveland Alzheimer’s Disease Research Center leverages the resources of many of the major health care institutions in northeast Ohio from Case Western Reserve University, Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, the MetroHealth System and University Hospitals. It is one of 31 Alzheimer’s Disease Centers around the country.
Prior to its creation, Ohioans had to travel to Ann Arbor, Pittsburgh, Indianapolis or Lexington, Ky.– the closest other ADRCs - to access the expertise of an NIA-funded Alzheimer’s Research Center. Dr. James Leverenz, Director of the Cleveland Alzheimer’s Research Center and Director of the Lou Ruvo Center for Brain Health at the Cleveland Clinic in Cleveland, said, “at this point all though we are well aware of the expertise at Ohio State and I believe there is some expertise in Toledo as well as down in Cincinnati, the (Research Center) grant itself focuses on northeast Ohio. The focus is really to provide a foundation to expand research on Alzheimer’s and related dementias…It’s creating an infrastructure for research to expand in the area.”

That infrastructure includes developing a structure to share research findings, engaging and enrolling a diverse group of individuals into observational studies, determining if basic science or animal model work can translate to human studies and providing expertise into other dementias like Lewy Body dementia. Data collected in Ohio helps researchers nationwide, Dr. Lerner said.

Dr. Nina Silverberg, Director of the Alzheimer’s Disease Research Centers Program at the National Institute on Aging, said, “the Ohio Center is unique in being connected to the National Prion Center and that is a wonderful addition to our network. The Center also brings additional expertise in Lewy Body dementia to the ADRC program.” She added that the Cleveland Center’s focus on translational therapeutics, which accelerates promising research into possible drug discoveries, is an area critical to the ADRC program and will help researchers reach the goal of finding treatments for these devastating diseases as quickly and as efficiently as possible.

Dr. Leverenz said the Cleveland Alzheimer’s Disease Center’s connection to the Cleveland-based National Prion Disease Pathology Surveillance Center at Case Western Reserve University is important because there are things researchers can learn from Prion diseases that can shed insight into Lewy Body dementia and Alzheimer’s diagnosis.

Additionally, Dr. Leverenz also leads the first U.S.-based Dementia with Lewy Bodies Consortium, an NIH-funded project with 10 sites around the country. An estimated 1.4 million Americans have Lewy Body dementia, which has some symptoms similar to Alzheimer’s disease.

Alzheimer’s disease, which impacts approximately 5.8 million Americans, is a fatal brain disease that currently cannot be prevented, slowed or cured. Dr. Lerner said, “before COVID, we had two epidemics, we had the Opioid epidemic and we have the Alzheimer’s epidemic…In my career, I have seen the number of Alzheimer’s cases go from 2 million to 4 million and now we are almost at 6 million.  We need some version of flattening the curve.”

At The Ohio State University, Dr. Douglas Scharre, Director of the Division of Cognitive Neurology and Director of the Center for Cognitive and Memory Disorders, said, the University has a strong track record in clinical research in areas such as genetics, pre-clinical diagnostic measures, imaging, health disparities and drug trials. He said he is seeing great new collaborations and innovations happening because researchers in other medical fields like cancer are bringing their techniques to the field of Alzheimer’s research.

“Since Congress has increased the budgets for the NIA there definitely has been an uptick of collaborative research here at Ohio State,” Dr. Scharre said. “It encourages individuals who may not have been working directly in the Alzheimer’s field to say, ‘I think I can apply my techniques and talents to the Alzheimer’s field,’ which is what we need.”

The Alzheimer's Association, which is the world's largest nonprofit funder of Alzheimer's disease research, has lobbied extensively for increased federal funding for Alzheimer’s and related dementia research at the NIH. Since 2011, annual federal Alzheimer’s research funding has increased from $448 million to $2.8 billion nationwide.

Ohio is getting a good share of the funding. According to the Blue Ridge Institute for Medical Research, an organization that each year publishes a ranking of NIH grant awards, last year Ohio ranked number 10 in the nation for NIH awards.

In addition, between 1993 and 2020, the Alzheimer’s Association has funded about $16 million in Ohio research projects.

Philanthropy and money from drug companies also drive new research initiatives. For example, on June 18, the Cleveland Clinic and The Women’s Alzheimer’s Movement opened the nation’s first Alzheimer’s prevention clinic for women at the Cleveland Clinic Lou Ruvo Center for Brain Health in Los Vegas. It is a philanthropy-driven effort.

Dr. Scharre said Alzheimer’s disease advances will follow the money. “It depends entirely on how much money goes into this,” he said. “Nothing moves without funds. If you just keep the funds where they are, it will take a longer time.”

Alzheimer's Association

The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia.™ For more information, visit or call the 24/7 Helpline at 800.272.3900.

Keep Up With Alzheimer’s News and Events

The first survivor of Alzheimer's is out there, but we won't get there without you.

Donate Now

Learn how Alzheimer’s disease affects the brain.

Take the Brain Tour

Don't just hope for a cure. Help us find one. Volunteer for a
clinical trial.

Learn More